BioInformant

Your Global Leader in Stem Cell Market Research

Home » Cell Therapy » Page 5

Nucleus Biologics Launches Krakatoa® K500: A Pod-Based, On-Demand Media and Buffer Manufacturing System Transforming Scale Bioproduction

By Leave a Comment

  • Produces 35–500 liters of sterile media and buffers on demand at point-of-use, reducing cost, complexity, and lead times
  • Pod-based, closed single-use system with integrated analytics, QR-code-driven execution, and automated digital batch records to support GMP-compliant manufacturing

San Diego, CA — February 10, 2026 — Nucleus Biologics, a leading provider of custom cell culture solutions and manufacturing technologies for advanced therapies, today announced the launch of Krakatoa® K500, the first bioreactor-scale, pod-based media and buffer manufacturing system designed to deliver sterile solutions on demand and at point-of-use. The system enables the co-location of cell culture media and buffer manufacturing and bioproduction. [Read more…]

Eli Lilly Commits Up to $2.4B to Orna Therapeutics in Major Bet on In Vivo CAR-T

By Leave a Comment

In news announced yesterday (February 9, 2026), Eli Lilly revealed plans to acquire Orna Therapeutics for up to $2.4 billion, a truly staggering price tag. The move marks a decisive step toward the next generation of cell therapy: programming immune cells directly inside the patient rather than manufacturing them outside the body.

Importantly, this transaction is not centered on a single pipeline candidate, but on securing a platform technology that could reshape how CAR-T and other immune-reset strategies are developed and delivered across autoimmune disease and beyond. [Read more…]

Big Pharma Makes M&A Moves to Secure Positions in In Vivo Cell Engineering

By Leave a Comment

Across 2025, a striking trend has emerged in biotechnology. Major pharmaceutical companies are racing to acquire in vivo cell engineering platforms, signaling that reprogramming cells inside the body has moved from speculative science to strategic priority.

In just a few months, the field has transformed. AstraZeneca, AbbVie, Gilead’s Kite Pharma, and Bristol Myers Squibb have all made acquisitions designed to accelerate their capabilities in in vivo cell therapy. Each deal highlights the growing importance of technologies that can directly engineer immune cells without removing them from the body. [Read more…]

Ways to Curb the Sky-high Costs of CAR-T Cell Therapy

By Leave a Comment

CAR-T therapy has revolutionized cancer treatment, offering a personalized approach that uses genetically modified T cells to target and destroy cancer cells. However, this breakthrough treatment comes at a steep price. In the U.S., CAR-T therapies are priced between $300,000 and $600,000, and when factoring in the costs of treating adverse reactions and hospital stays, the total expenditure can exceed $1,000,000. The high cost makes it inaccessible for many patients and poses a challenge for healthcare systems worldwide.

To address this issue, experts and industry leaders have proposed several strategies to reduce the cost of CAR-T therapy while maintaining its efficacy and accessibility. [Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0